|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Patient No** | **Age** | **Gender** | **Entity** | **Histopathology, Location** | **Tumor sites (primary and metastatic)\*** | **ECOG** | **n previous local therapies** | **n previous systemic therapies** | **Previous systemic therapies** | **Concomitant therapy** | **First Subsequent therapy** | **68Ga-FAPI-46 SUVmax\*** | **68Ga-FAPI-46 SUVmean\*** | **Follow-up (months)** | **Status** | **RECIST response after RLT†** | **PERCIST response after RLT** |
| 1 | 61 | male | Sarcoma | SFT (lung) | Lung, pleura | 1 | 2 | 3 | Doxorubicin, Sunitinib, Bevacizumab/Temozolomide | - | Trabectedin | 25.0 | 10.5 | 18.4 | follow-up | SD | SMD |
| 2 | 54 | female | Sarcoma | Fibrosarcoma (occipital) | Lung, lymph nodes pancreas, bone | 1 | 6 | 6 | Doxorubicin/Ifosfamide, Gemcitabine/DTIC, Trabectedin, Doxorubicin/Ifosfamid rechallenge, Pazopanib, Gemcitabine/Docetaxel | - | Re-challenge Doxorubicin, | 18.3 | 9.4 | 14.4 | deceased | SD | PMD |
| 3 | 57 | female | Sarcoma | SFT (retroperitoneal) | Peritoneum, soft tissue, bone | 1 | 6 | 3 | Doxorubicin/Olaratumab, Bevacizumab/Temozolomide, Sunitinib | - | - | 166.1 | 91.2 | 13.5 | follow-up | PR | SMD |
| 4 | 63 | female | Sarcoma | Gastrointestinal neuroectodermal tumor | Lung, liver, lymph nodes, bone, soft tissue | 1 | 1 | 3 | Doxorubicin/Olaratumab, Pazopanib, Trabectedin | - | Nivolumab | 16.1 | 14.0 | 12.0 | follow-up | SD | N/A |
| 5 | 67 | female | Sarcoma | SFT (Thorax), Breast cancer | Pleura, thyroid, lung, bone, brain, soft tissue, cervical | 1 | 8 | 4 | SFT: Doxorubicin, Pazopanib, Temozolomide/Bevacizumab  Breast cancer: Carboplatin/Paclitaxel | - | Nab-paclitaxel plus Atezolizumab for relapse breast cancer | 102.1 | 73.4 | 10.2 | deceased | SD | SMD |
| 6 | 64 | female | Sarcoma | SFT (Pleura) | Pleura, pancreas, muscle, lung | 1 | 3 | 3 | Sunitinib, Temozolomide/Bevacizumab, Pazopanib | - | Doxorubicin and Ifosfamid | 32.9 | 14.9 | 10.0 | deceased | PD | SMD |
| 7 | 71 | female | Sarcoma | SFT (intrathoracic) | Pleura | 1 | 3 | 2 | Sunitinib, Bevacizumab/Temozolomide | - | - | 25.7 | 12.9 | 8.8 | follow-up | SD | SMD |
| 8 | 83 | female | Sarcoma | SFT (bipulmonary) | Lung | 1 | 1 | 0 | - | - | - | 23.0 | 14.5 | 7.4 | follow-up | SD | SMD |
| 9 | 58 | female | Sarcoma | SFT (thigh) | Soft tissue, bone, lung, liver, peritoneum | 2 | 5 | 3 | Sunitinib, Doxorubicin/Ifosfamide, Temozolomide/Bevacizumab | - | Trabectedin | 29.1 | 25.7 | 7.3 | deceased | PD | SMD |
| 10 | 61 | male | Sarcoma | Chondrosarcoma (femur/pelvic) | Lung, lymph nodes, pancreas, bone | 2 | 2 | 1 | Carboplatin/Doxorubicin/Ifosfamide | - | Etoposid | 16.7 | 7.4 | 6.6 | deceased | PD | PMD |
| 11 | 55 | male | Sarcoma | Spindle cell sarcoma (kidney) | Kidney, liver, lung, pleura | 1 | 6 | 6 | Sunitinib, Bevacizumab/Temozolomide, Trabectedin/Olaparib, Doxorubicin/Dacarbazin, Axitinib/Prembrolizumab, Gemcitabine/Docetaxel | - | liposom. Doxorubicin, Radiatio | 28.0 | 16.5 | 6.1 | deceased | PD | PMD |
| 12 | 71 | female | Sarcoma | Leiomyosarcoma (uterus) | Liver, lung, muscle, peritoneum, lymph nodes | 0 | 6 | 5 | Doxorubicin/Ifosfamide, Gemcitabine/DTIC, Gemcitabine/DTIC rechallenge, Pazopanib, Trabectedin, Eribulin | - | Re-challenge Trabectedin | 20.9 | 7.6 | 4.2 | follow-up | PD | N/A |
| 13 | 66 | male | Sarcoma | Chordoma (lumbar spine) | Bone, soft tissue, liver, lung, lymph nodes | 3 | 3 | 2 | Imatinib/Sirolimus, Carboplatin/Etoposid | - | Nivolumab | 22.3 | 10.4 | 2.2 | deceased | N/A | SMD |
| 14 | 36 | male | Sarcoma | SFT (paralumbal left) | Lung, soft tissue, lymph nodes | 0 | 8 | 8 | Doxorubicin/Ifosfamide, Pazopanib, Gemcitabine, Trabectedin, Bevacizumab/Temozolomide, Ponatinib, Dacarbazin, Trabectedin/Olaparib | - | - | 35.9 | 16.0 | 1.0 | follow-up | N/A | N/A |
| 15 | 22 | male | Sarcoma | Ostoblastic osteosarcoma (proximal left humerus) | Lung, heart, lymph nodes | 2 | 6 | 6 | EURAMOS-protocol, Carboplatin/Etoposid, Sirolimus, OTIE-protocol, NCT-PMO-1603\_TOP-ART-protocol, Cabozantinib | - | - | 12.1 | 10.6 | 0.8 | deceased | N/A | N/A |
| 16 | 64 | male | Sarcoma | SFT (abdominal) | Lung, soft tissue | 0 | 3 | 3 | Doxorubicin/Ifosfamide, Bevacizumab/Temozolomide, Bevacizumab maintenance | - | - | 28.9 | 15.7 | 0.1 | follow-up | N/A | N/A |
| 17 | 56 | female | PDAC | Adenocarcinoma | Pancreas, liver, lung, lymph nodes, adrenal gland | 2 | 0 | 6 | FOLFIRINOX, Gemcitabine/NabPaclitaxel, Trabectedin/Olaparib, Gemcitabine/Cisplatin, Capecitabine/Cisplatin, Afatinib | Afatinib | - | 16.5 | 12.7 | 3.4 | deceased | SD | N/A |
| 18 | 57 | female | PDAC | Adenocarcinoma | Liver, lung, lymph nodes, bone | 3 | 2 | 2 | Gemcitabine, NabPaclitaxel | - | Cisplatin | 14.9 | 7.9 | 1.9 | deceased | PD | PMD |
| 19 | 61 | female | PDAC | Adenocarcinoma | Pancreas, liver, lung, lymph nodes, bone | 2 | 1 | 9 | Gemcitabine/NabPaclitaxel, Gemcitabine/NabPaclitaxel, PEGPH20/Azetolizumab, FOLFIRINOX, Olaparib, Gemcitabine/Cisplatin, FOLFIRINOX, Mitomycine, Trametinib/HCQ | Trametinib | - | 19.4 | 10.6 | 1.3 | deceased | PD | PMD |
| 20 | 81 | male | Prostate Cancer | Adenocarcinoma | Bone, prostate | 0 | 1 | 5 | Degarelix, Docetaxel, Abiraterone, Enzalutamide, Radium-223 | Denosumab | Enzalutamide, Cabazitaxel | 11.5 | 8.8 | 4.2 | follow-up | N/A | PMD |
| 21 | 38 | female | Gastric Cancer | Adenocarcinoma | Stomach, lymph nodes, liver, peritoneum, spleen | 2 | 1 | 4 | FLOT-protocol, FLOT-protocol, FOLFIRI, Paclitaxel/Ramucircumab | - | - | 12.2 | 8.9 | 2.2 | follow-up | PD | N/A |

**Supplemental Table 1: Individual patient characteristics.** \*on screening PET: SUVmax for one hottest lesion, average SUVmean for five largest lesions. SFT, solitary fibrous tumor. †primary endpoint.